OS Therapies Inc. Appoints New CMO and Director
Ticker: OSTX · Form: 8-K · Filed: Oct 28, 2024 · CIK: 1795091
| Field | Detail |
|---|---|
| Company | Os Therapies Inc (OSTX) |
| Form Type | 8-K |
| Filed Date | Oct 28, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, appointment, director
TL;DR
OS Therapies just swapped a director for a CMO/Director role for Dr. David J. E. Smith. Big changes ahead?
AI Summary
OS Therapies Inc. announced on October 28, 2024, the departure of director Dr. David J. E. Smith and the appointment of Dr. David J. E. Smith as Chief Medical Officer. The company also announced the election of Dr. David J. E. Smith to its Board of Directors. These changes are effective immediately.
Why It Matters
The appointment of a new Chief Medical Officer and a director can signal strategic shifts or new leadership focus within the company's drug development or operational strategies.
Risk Assessment
Risk Level: medium — Changes in key leadership roles like CMO and board members can indicate significant strategic shifts or internal challenges, warranting closer monitoring.
Key Players & Entities
- OS Therapies Inc. (company) — Registrant
- Dr. David J. E. Smith (person) — Departing Director, Appointed Chief Medical Officer, Elected Director
- October 28, 2024 (date) — Effective date of changes
FAQ
What were the specific reasons for Dr. David J. E. Smith's departure as a director?
The filing states Dr. Smith departed as a director but was simultaneously appointed as Chief Medical Officer and elected to the Board of Directors, suggesting a role change rather than a complete departure.
What is the effective date of Dr. David J. E. Smith's appointment as Chief Medical Officer?
The filing indicates the changes, including the appointment of Dr. David J. E. Smith as Chief Medical Officer, are effective October 28, 2024.
What is the primary focus of OS Therapies Inc.?
OS Therapies Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
When was OS Therapies Inc. incorporated and in which state?
OS Therapies Inc. was incorporated in Delaware.
What is the principal executive office address for OS Therapies Inc.?
The principal executive offices are located at 115 Pullman Crossing Road, Suite 103, Grasonville, Maryland 21638.
Filing Stats: 1,273 words · 5 min read · ~4 pages · Grade level 11 · Accepted 2024-10-28 16:55:45
Key Financial Figures
- $0.001 — ch Registered Common Stock, par value $0.001 per share OSTX NYSE American Indi
Filing Documents
- ea0218797-8k_osthera.htm (8-K) — 36KB
- ea021879701ex99-1_osthera.htm (EX-99.1) — 15KB
- 0001213900-24-091235.txt ( ) — 232KB
- ostx-20241028.xsd (EX-101.SCH) — 3KB
- ostx-20241028_lab.xml (EX-101.LAB) — 33KB
- ostx-20241028_pre.xml (EX-101.PRE) — 22KB
- ea0218797-8k_osthera_htm.xml (XML) — 4KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2024 OS THERAPIES INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-42195 82-5118368 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 115 Pullman Crossing Road , Suite 103 Grasonville , Maryland 21638 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: ( 410 ) 297-7793 N/A (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share OSTX NYSE American Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. CURRENT REPORT ON FORM 8-K OS Therapies Incorporated (the "Company") October 28, 2024 Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignations Effective October 28, 2024, Colin Goddard, Ph.D. notified the Board of Directors (the "Board") of the Company of his resignation as the Chairman of the Board and director of the Company, effective immediately. Also, effective October 28, 2024, Joacim Borg notified the Board of his resignation as a director, effective immediately. Neither Dr. Goddard's nor Mr. Borg's resignation resulted from any disagreement with the Company's operations, policies or practices. Appointments Effective October 28, 2024, the Company appointed two new directors to fill the resulting director vacancies on the Board. Avril McKean Dieser and Olivier R. Jarry joined the Board, effective October 28, 2024. Avril McKean Dieser Ms. McKean Dieser, age 51, is currently the Vice President, Head of Legal Patient Evidence of UCB, Inc., a subsidiary of UCB, S.A., a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or the central nervous system, since August 2016, and previously from April 2008 to April 2013. At UCB, she leads a team of attorneys supporting UCB's global assets, global payer functions, and regulatory, medical and patient communities, including clinical development. Ms. McKean Dieser was formerly a member of the AbbVie Inc. legal team providing global product support for the immunology and oncology franchises and was the government pricing lawyer for all pharmaceutical and combination products from May 2013 to July 2016. Prior to joining the pharmaceutical industry, Ms. McKean Dieser practiced corporate law in Atlanta, Georgia at two nationally recognized law firms. She earned her J.D. degree from The Catholic University Columbus School of Law and is admitted to practice law in the states of Georgia and Illinois. Prior to receiving her law degree, Ms. McKean Dieser received an M.A. in Public Administration from the University of Maryland, European Division and a B.A. degree in English Literature from Duquesne University. Ms. McKean Dieser lost her son, Edward, to Osteosarcoma in January 2024 at the age of 21. Ms. McKean Dieser is well qualified to serve as a director of the Company due to her substantial knowledge of the pharmaceutical regulatory and commercialization environment and more than 21 years of working experience in corporate controls and governance. Olivier R. Jarry Mr. Jarry, age 63, is currently the Co-founder and Chief Executive Officer of Libera Bio S.L., a private Spanish biopharmaceutical company devoted to the development of a new class of precision therape